Top accelerator startups

14,448 startups · 29 programs

Nephrogen

Active · Curative genetic medicines for kidney diseases

8signal of 100 · rising 2
  • team of 5Team size · YC's directory+4
  • went through YCProgram · this site+4

A sum of public facts, not a judgement and not investment advice.

Competitors

Adjacent

Also from S20 in AI

All of S20

About Nephrogen

Nephrogen is a Stanford biotech spin-out developing curative genetic medicines for kidney and pancreatic diseases. Kidney disease alone affects 1 in 7 Americans, and neither indication has any approved gene-based therapies. Nephrogen's underlying platform combines AI and high-throughput screening to engineer safer, more efficient, and less expensive gene delivery vehicles for reaching the kidney and pancreas, and has attracted non-dilutive funding from seven major pharmaceutical companies including Merck KGaA, Novartis, and Bristol Myers Squibb.

YC batch
S20 · Summer 2020
Status, per YC
Active
Category
AI
Team size
5
Location
New York City, NY, USA
Checked
13h ago

YC tags: Gene Therapy, CRISPR, Biotech

Nephrogen in S20: 209 companies, 28% AI

Nephrogen: questions

Which YC batch was Nephrogen in?

Nephrogen was in Y Combinator's Summer 2020 batch (S20).

Is Nephrogen still active?

Y Combinator lists Nephrogen as active.

Where is Nephrogen based?

Nephrogen lists New York City, NY, USA as its location on YC's directory.